AbCellera Biologics Inc. vs Abbott Laboratories · latest fiscal year · computed from SEC XBRL filings
| Metric | ABCL | ABT |
|---|---|---|
| Revenue | $75.1M | $44.33B |
| Revenue growth (YoY) | 160.6% | 5.7% |
| Operating margin | -289.0% | 18.2% |
| Net margin | -194.9% | 14.7% |
| FCF margin | -231.7% | 16.7% |
| Capex % of revenue | 56.9% | 4.9% |
Want ABCL against its full peer set, not just ABT?
The CompsDesk pack: up to 12 peers you choose, up to 14 metrics (6 core guaranteed), trends for every filed year (up to five), a citation on every number — board-ready PDF + CSV, $249.
Green = better on that metric where direction is unambiguous. Source: SEC EDGAR XBRL (10-K). "n/a" = not disclosed under mapped tags; never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.